Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 89Other hematologic neoplasm 34Plasma cell 20Sarcoma 7Dermatologic 6Myeloid 5Genitourinary 4CNS 4Head & Neck 3Gastrointestinal 3Thoracic 2Breast 2Other neoplasm 1Gynecologic 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 297Lung Neoplasms 195Colorectal Neoplasms 54Small Cell Lung Carcinoma 52Neoplasms 39Ovarian Neoplasms 38Melanoma 37Pancreatic Neoplasms 33Breast Neoplasms 31Neoplasm Metastasis 27Stomach Neoplasms 26Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Renal Cell 22Urinary Bladder Neoplasms 20Prostatic Neoplasms 20Esophageal Neoplasms 20Endometrial Neoplasms 20Head and Neck Neoplasms 19Triple Negative Breast Neoplasms 18Colonic Neoplasms 18Uterine Cervical Neoplasms 16Carcinoma, Hepatocellular 16Mesothelioma 15Lung Diseases 13Sarcoma 12Parkinson Disease 4, Autosomal Dominant Lewy Body 12Mesothelioma, Malignant 12Adenocarcinoma of Lung 11Cholangiocarcinoma 10Rectal Neoplasms 9

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Thoracic × 30 days × Clear all
NCT05751798 2026-06-04

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

OSE Immunotherapeutics

Phase 1/2 Recruiting
41 enrolled
LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡